首页 > 最新文献

Pediatric Critical Care Medicine最新文献

英文 中文
The 2024 Phoenix Sepsis Score Criteria: Part 4, What About Using World-Oriented Criteria?
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1097/PCC.0000000000003663
Matthew O Wiens, Enitan D Carrol, Mohammod Jobayer Chisti, Daniela Carla de Souza, Rakesh Lodha, Suchitra Ranjit, Niranjan Kissoon
{"title":"The 2024 Phoenix Sepsis Score Criteria: Part 4, What About Using World-Oriented Criteria?","authors":"Matthew O Wiens, Enitan D Carrol, Mohammod Jobayer Chisti, Daniela Carla de Souza, Rakesh Lodha, Suchitra Ranjit, Niranjan Kissoon","doi":"10.1097/PCC.0000000000003663","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003663","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e262-e265"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2024 Phoenix Sepsis Score Criteria: Part 5, What About "Parsimony" in the Criteria-Is Less Really More?
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1097/PCC.0000000000003665
Adrienne G Randolph, Mark W Hall, Niranjan Kissoon, Daniela Carla de Sousa, Mohammod Jobayer Chisti, Enitan D Carrol
{"title":"The 2024 Phoenix Sepsis Score Criteria: Part 5, What About \"Parsimony\" in the Criteria-Is Less Really More?","authors":"Adrienne G Randolph, Mark W Hall, Niranjan Kissoon, Daniela Carla de Sousa, Mohammod Jobayer Chisti, Enitan D Carrol","doi":"10.1097/PCC.0000000000003665","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003665","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e266-e271"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Phoenix Sepsis Score in Pediatric Oncology Patients With Sepsis at PICU Admission: Test of Performance in a European Multicenter Cohort, 2018-2020.
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1097/PCC.0000000000003683
Roelie M Wösten-van Asperen, Hannah M la Roi-Teeuw, Wim J E Tissing, Iolanda Jordan, Christian Dohna-Schwake, Gabriella Bottari, John Pappachan, Roman Crazzolara, Angela Amigoni, Agnieszka Mizia-Malarz, Andrea Moscatelli, María Sánchez-Martín, Jef Willems, Luregn J Schlapbach

Objectives: The Pediatric Sepsis Definition Task Force developed and validated a new organ dysfunction score, the Phoenix Sepsis Score (PSS), as a predictor of mortality in children with suspected or confirmed infection. The PSS showed improved performance compared with prior scores. However, the criteria were derived in a general pediatric population, in which only 10% had cancer. Given that pediatric cancer patients with sepsis have higher mortality compared with noncancer patients with sepsis, we aimed to assess the PSS in PICU patients with cancer and sepsis.

Design: Retrospective multicenter cohort study.

Setting: Twelve PICUs across Europe.

Patients: Each PICU identified patients 18 years young or younger, with underlying malignancy and suspected or proven sepsis, and admission between January 1, 2018, and January 1, 2020.

Interventions: None.

Measurements and main results: The PSS and three other scores, including Phoenix-8, Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score, and pediatric Sequential Organ Failure Assessment (pSOFA) score, were calculated for comparison. The primary outcome was 90-day all-cause mortality. We compared score performance using area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) analyses. Among 383 patients with proven or suspected sepsis, 90-day mortality was 19.3% (74/383). We failed to identify an association between a particular score and performance for 90-day mortality. The mean (95% CI) values for the AUROC of each score was: PSS 0.66 (0.59-0.72), Phoenix-8 0.65 (0.58-0.72), PELOD-2 0.64 (0.57-0.71), and pSOFA 0.67 (0.60-0.74) and for the AUPRC of each score: PSS 0.32 (0.23-0.42), Phoenix-8 0.32 (0.23-0.42), PELOD-2 0.32 (0.22-0.43), and pSOFA 0.36 (0.26-0.46). Similar results were obtained for PICU mortality or sepsis-related PICU mortality.

Conclusions: Contrary to the general PICU population, our retrospective test of the PSS in a PICU oncology dataset with suspected or proved sepsis from European PICUs, 2018-2020, failed to identify improved performance in association with mortality. This unique patient population deserves development of organ dysfunction scores that reflect organ dysfunction and mortality data specifically from these patients and will require prospective validation in future studies.

目的:儿科败血症定义工作组开发并验证了一种新的器官功能障碍评分,即凤凰城败血症评分(PSS),作为预测疑似或确诊感染患儿死亡率的指标。与之前的评分相比,PSS 的表现有所改善。然而,该标准是在普通儿科人群中得出的,其中只有 10%的人患有癌症。鉴于患有败血症的儿科癌症患者的死亡率高于患有败血症的非癌症患者,我们旨在对患有癌症和败血症的 PICU 患者的 PSS 进行评估:设计:回顾性多中心队列研究:背景:欧洲的 12 个 PICU:每个PICU确定年龄在18岁或以下、患有基础恶性肿瘤、疑似或已证实患有脓毒症、在2018年1月1日至2020年1月1日期间入院的患者:无:计算PSS和其他三个评分,包括Phoenix-8、儿科逻辑器官功能障碍-2(PELOD-2)评分和儿科序贯器官衰竭评估(pSOFA)评分,以进行比较。主要结果是 90 天全因死亡率。我们使用接收者操作特征曲线下面积(AUROC)和精确度-召回曲线下面积(AUPRC)分析比较了评分性能。在 383 名确诊或疑似败血症患者中,90 天死亡率为 19.3%(74/383)。我们未能发现特定评分与 90 天死亡率之间存在关联。各评分的 AUROC 平均值(95% CI)为PSS 0.66 (0.59-0.72)、Phoenix-8 0.65 (0.58-0.72)、PELOD-2 0.64 (0.57-0.71)和 pSOFA 0.67 (0.60-0.74),各评分的 AUPRC 平均值分别为PSS为0.32(0.23-0.42),Phoenix-8为0.32(0.23-0.42),PELOD-2为0.32(0.22-0.43),pSOFA为0.36(0.26-0.46)。PICU死亡率或与败血症相关的PICU死亡率也得到了类似的结果:与普通PICU人群相反,我们在2018-2020年欧洲PICU肿瘤疑似或确诊败血症数据集中对PSS进行的回顾性测试未能发现与死亡率相关的性能改善。这一独特的患者群体值得开发专门反映这些患者器官功能障碍和死亡率数据的器官功能障碍评分,并需要在未来的研究中进行前瞻性验证。
{"title":"The Phoenix Sepsis Score in Pediatric Oncology Patients With Sepsis at PICU Admission: Test of Performance in a European Multicenter Cohort, 2018-2020.","authors":"Roelie M Wösten-van Asperen, Hannah M la Roi-Teeuw, Wim J E Tissing, Iolanda Jordan, Christian Dohna-Schwake, Gabriella Bottari, John Pappachan, Roman Crazzolara, Angela Amigoni, Agnieszka Mizia-Malarz, Andrea Moscatelli, María Sánchez-Martín, Jef Willems, Luregn J Schlapbach","doi":"10.1097/PCC.0000000000003683","DOIUrl":"10.1097/PCC.0000000000003683","url":null,"abstract":"<p><strong>Objectives: </strong>The Pediatric Sepsis Definition Task Force developed and validated a new organ dysfunction score, the Phoenix Sepsis Score (PSS), as a predictor of mortality in children with suspected or confirmed infection. The PSS showed improved performance compared with prior scores. However, the criteria were derived in a general pediatric population, in which only 10% had cancer. Given that pediatric cancer patients with sepsis have higher mortality compared with noncancer patients with sepsis, we aimed to assess the PSS in PICU patients with cancer and sepsis.</p><p><strong>Design: </strong>Retrospective multicenter cohort study.</p><p><strong>Setting: </strong>Twelve PICUs across Europe.</p><p><strong>Patients: </strong>Each PICU identified patients 18 years young or younger, with underlying malignancy and suspected or proven sepsis, and admission between January 1, 2018, and January 1, 2020.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>The PSS and three other scores, including Phoenix-8, Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score, and pediatric Sequential Organ Failure Assessment (pSOFA) score, were calculated for comparison. The primary outcome was 90-day all-cause mortality. We compared score performance using area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) analyses. Among 383 patients with proven or suspected sepsis, 90-day mortality was 19.3% (74/383). We failed to identify an association between a particular score and performance for 90-day mortality. The mean (95% CI) values for the AUROC of each score was: PSS 0.66 (0.59-0.72), Phoenix-8 0.65 (0.58-0.72), PELOD-2 0.64 (0.57-0.71), and pSOFA 0.67 (0.60-0.74) and for the AUPRC of each score: PSS 0.32 (0.23-0.42), Phoenix-8 0.32 (0.23-0.42), PELOD-2 0.32 (0.22-0.43), and pSOFA 0.36 (0.26-0.46). Similar results were obtained for PICU mortality or sepsis-related PICU mortality.</p><p><strong>Conclusions: </strong>Contrary to the general PICU population, our retrospective test of the PSS in a PICU oncology dataset with suspected or proved sepsis from European PICUs, 2018-2020, failed to identify improved performance in association with mortality. This unique patient population deserves development of organ dysfunction scores that reflect organ dysfunction and mortality data specifically from these patients and will require prospective validation in future studies.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e177-e185"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What Do We Know About Pediatric Sepsis Scoring Post-Phoenix?
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1097/PCC.0000000000003690
Robert C Tasker
{"title":"What Do We Know About Pediatric Sepsis Scoring Post-Phoenix?","authors":"Robert C Tasker","doi":"10.1097/PCC.0000000000003690","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003690","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e237-e240"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Citrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes. 枸橼酸抗凝在持续肾替代治疗中:滤器相关结果的多中心PICU研究。
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2024-12-19 DOI: 10.1097/PCC.0000000000003661
Hasan S Kihtir, Muhterem Duyu, Mehmet E Mementoglu, Ilknur Tolunay, Tanil Kendirli, Faruk Ekinci, Edin Botan, Ebru A Ongun, Ayse Asik, Emrah Gun, Hacer Ucmak, Esra Sevketoglu, Dincer Yildizdas

Objectives: To examine citrate anticoagulation in continuous renal replacement therapy (CRRT) in the PICU.

Design: Post hoc analysis of a curated, multicenter dataset collected from January 1, 2022, to June 1, 2023.

Setting: Seven PICUs in Turkey.

Patients: PICU admissions in need of CRRT, 28 days to 18 years old.

Interventions: None.

Measurements and main results: In 128 filters used in 73 patients, the effective filter life (EFL) restricted to 72 hours was a median (interquartile range [IQR]) of 40.5 hours (IQR, 21-58 hr); total EFL was a median of 59 hours (IQR, 28-89 hr). Analysis of the receiver operating characteristic curve for initial citrate infusion dose (CID) and whether EFL reached 72 hours identified a cutoff level for initial CID of greater than 2.64 mmol citrate per liter of patient blood flow (mmol/L-bf). As expected, the two filter groups categorized by initial CID (≥ 2.7 vs. < 2.7 mmol/L-bf) showed filters in children receiving higher initial dosing had longer total EFL (72 hr [IQR, 48-104 hr] vs. 38.5 hr [IQR, 18-84 hr]; p = 0.03). We failed to identify an association between CRRT for over 24 or 48 hours and greater odds (odds ratio [OR], 95% CI) of citrate accumulation (OR, 2.23; 95% CI, 0.82-6.13; p = 0.118 or OR, 1.78; 95% CI, 0.84-3.8; p = 0.134, respectively). However, we cannot exclude up to 6.1- or 3.8-fold odds of citrate accumulation; of note, CRRT over 72 hours was associated with greater odds of citrate accumulation (OR, 2.17; 95% CI, 1.01-4.68; p = 0.04). Citrate lock syndrome occurred in eight of 128 (6.3%; 95% CI, 3-11.4%) filters, and resolved without termination of CRRT. On multivariable analysis, a higher patient initial lactate concentration was associated with an 18% (95% CI, 7-30%) greater hazard of developing citrate accumulation.

Conclusions: Citrate anticoagulation for CRRT is an option for children. Choosing an initial CID greater than or equal to 2.7 mmol/L-bf provides longer EFL but with the associated potential of citrate accumulation. Further studies are needed on initial CID and duration of EFL.

目的:探讨PICU持续肾替代治疗(CRRT)中柠檬酸盐抗凝作用。设计:对2022年1月1日至2023年6月1日收集的一个精心策划的多中心数据集进行事后分析。背景:土耳其的7个picu。患者:PICU入院,需要CRRT, 28天至18岁。干预措施:没有。测量结果和主要结果:在73例患者使用的128个过滤器中,有效过滤器寿命(EFL)限制为72小时,中位数(四分位数间距[IQR])为40.5小时(IQR, 21-58小时);总EFL中位数为59小时(IQR, 28-89小时)。通过对初始柠檬酸滴注剂量(CID)和EFL是否达到72小时的受试者工作特征曲线分析,确定了初始CID大于2.64 mmol柠檬酸每升患者血流量(mmol/L-bf)的临界值。正如预期的那样,按初始CID(≥2.7 vs < 2.7 mmol/L-bf)分类的两个过滤器组显示,接受较高初始剂量的过滤器的儿童总EFL更长(72小时[IQR, 48-104小时]对38.5小时[IQR, 18-84小时];P = 0.03)。我们未能确定超过24或48小时的CRRT与柠檬酸盐积累的较大几率(比值比[or], 95% CI)之间的关联(or, 2.23;95% ci, 0.82-6.13;p = 0.118或or, 1.78;95% ci, 0.84-3.8;P = 0.134)。然而,我们不能排除高达6.1或3.8倍的柠檬酸盐积累几率;值得注意的是,超过72小时的CRRT与更大的柠檬酸盐积累几率相关(OR, 2.17;95% ci, 1.01-4.68;P = 0.04)。128例中有8例发生柠檬酸锁综合征(6.3%;95% CI, 3-11.4%)筛选,没有终止CRRT。在多变量分析中,较高的患者初始乳酸浓度与18% (95% CI, 7-30%)发生柠檬酸盐积累的风险相关。结论:柠檬酸盐抗凝治疗CRRT是儿童的一种选择。选择大于或等于2.7 mmol/L-bf的初始CID可以提供更长的EFL,但与柠檬酸盐积累的潜力相关。对EFL的初始CID和持续时间需要进一步的研究。
{"title":"Citrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes.","authors":"Hasan S Kihtir, Muhterem Duyu, Mehmet E Mementoglu, Ilknur Tolunay, Tanil Kendirli, Faruk Ekinci, Edin Botan, Ebru A Ongun, Ayse Asik, Emrah Gun, Hacer Ucmak, Esra Sevketoglu, Dincer Yildizdas","doi":"10.1097/PCC.0000000000003661","DOIUrl":"10.1097/PCC.0000000000003661","url":null,"abstract":"<p><strong>Objectives: </strong>To examine citrate anticoagulation in continuous renal replacement therapy (CRRT) in the PICU.</p><p><strong>Design: </strong>Post hoc analysis of a curated, multicenter dataset collected from January 1, 2022, to June 1, 2023.</p><p><strong>Setting: </strong>Seven PICUs in Turkey.</p><p><strong>Patients: </strong>PICU admissions in need of CRRT, 28 days to 18 years old.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>In 128 filters used in 73 patients, the effective filter life (EFL) restricted to 72 hours was a median (interquartile range [IQR]) of 40.5 hours (IQR, 21-58 hr); total EFL was a median of 59 hours (IQR, 28-89 hr). Analysis of the receiver operating characteristic curve for initial citrate infusion dose (CID) and whether EFL reached 72 hours identified a cutoff level for initial CID of greater than 2.64 mmol citrate per liter of patient blood flow (mmol/L-bf). As expected, the two filter groups categorized by initial CID (≥ 2.7 vs. < 2.7 mmol/L-bf) showed filters in children receiving higher initial dosing had longer total EFL (72 hr [IQR, 48-104 hr] vs. 38.5 hr [IQR, 18-84 hr]; p = 0.03). We failed to identify an association between CRRT for over 24 or 48 hours and greater odds (odds ratio [OR], 95% CI) of citrate accumulation (OR, 2.23; 95% CI, 0.82-6.13; p = 0.118 or OR, 1.78; 95% CI, 0.84-3.8; p = 0.134, respectively). However, we cannot exclude up to 6.1- or 3.8-fold odds of citrate accumulation; of note, CRRT over 72 hours was associated with greater odds of citrate accumulation (OR, 2.17; 95% CI, 1.01-4.68; p = 0.04). Citrate lock syndrome occurred in eight of 128 (6.3%; 95% CI, 3-11.4%) filters, and resolved without termination of CRRT. On multivariable analysis, a higher patient initial lactate concentration was associated with an 18% (95% CI, 7-30%) greater hazard of developing citrate accumulation.</p><p><strong>Conclusions: </strong>Citrate anticoagulation for CRRT is an option for children. Choosing an initial CID greater than or equal to 2.7 mmol/L-bf provides longer EFL but with the associated potential of citrate accumulation. Further studies are needed on initial CID and duration of EFL.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e216-e226"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antithrombin and Activated Protein C in Pediatric Sepsis: Prospective Observational Study of Outcome. 儿童败血症的抗凝血酶和活化蛋白C:结果的前瞻性观察研究。
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2024-12-24 DOI: 10.1097/PCC.0000000000003677
Tran Dang Xoay, Ta Anh Tuan, Nguyen Thi Ha, Thieu Quang Quan, Nguyen Thi Duyen, Tran Thi Kieu My

Objectives: To assess antithrombin and activated protein C (aPC) levels in relation to disseminated intravascular coagulation (DIC) and severe outcomes in pediatric sepsis.

Design: Prospective, observational study conducted between April 2023 and October 2024. Coagulation profiles including conventional coagulation, antithrombin activity, and aPC were obtained at PICU admission.

Setting: PICU in the Vietnam National Children's Hospital, Hanoi, Vietnam.

Subjects: PICU admissions, 1 month to 18 years old, with sepsis.

Interventions: None.

Measurements and main results: One hundred thirty children (78 males; median age 7.5 mo) with mortality 23/130 (17.7%). The prevalence of overt DIC was 37 of 130 (28.5%). Nonsurvival at 28 days, compared with survival, was associated with hemorrhage and/or thrombosis at presentation, and higher number of dysfunctional organs, and overt DIC. Those with overt DIC, compared with not, had longer activated partial thromboplastin time, higher international normalized ratio and d -dimer, and lower antithrombin, and aPC. Activity of antithrombin and aPC correlated inversely with the Vasoactive-Inotropic Score in survivors ( p = 0.002 and 0.009, respectively). Patients with a cutoff value for antithrombin less than 63.5% had a mortality risk with area under the receiver operating characteristic (AUROC) curve 0.64, with sensitivity 0.51 and specificity 0.74, and positive predictive value 0.30. Regarding overt DIC, a cutoff value for antithrombin less than 55.5% had an AUROC 0.78, sensitivity 0.72 and specificity of 0.73, and positive predictive value 0.52.

Conclusions: In this observational study of pediatric sepsis patients, first 24-hour coagulation data in those who did not-survive to 28 days, vs. survivors showed an associated prior lower level of antithrombin in nonsurvivors. Furthermore, using the outcome of overt DIC and nonovert DIC in the first 72 hours, we found that lower levels of antithrombin or aPC are each associated with overt DIC and nonovert DIC in pediatric sepsis. Further validation work is needed in larger case series of pediatric sepsis.

目的:评估抗凝血酶和活化蛋白C (aPC)水平与儿童败血症弥散性血管内凝血(DIC)和严重结局的关系。设计:前瞻性观察性研究,于2023年4月至2024年10月进行。在PICU入院时获得常规凝血、抗凝血酶活性和aPC。地点:越南河内,越南国立儿童医院PICU。受试者:PICU入院,1个月至18岁,脓毒症。干预措施:没有。测量结果及主要结果:儿童130名(男78名;中位年龄7.5个月),死亡率23/130(17.7%)。显性DIC患病率为37 / 130(28.5%)。与存活患者相比,28天未存活患者出现出血和/或血栓形成,功能障碍器官数量增多,以及明显的DIC。与非DIC患者相比,明显DIC患者活化的部分凝血活素时间更长,国际标准化比率和d-二聚体更高,抗凝血酶和aPC更低。幸存者抗凝血酶和aPC活性与血管活性-肌力评分呈负相关(p分别= 0.002和0.009)。抗凝血酶临界值小于63.5%的患者死亡风险为AUROC曲线下面积0.64,敏感性0.51,特异性0.74,阳性预测值0.30。对于显性DIC,抗凝血酶小于55.5%的临界值AUROC为0.78,敏感性为0.72,特异性为0.73,阳性预测值为0.52。结论:在这项针对儿童败血症患者的观察性研究中,未存活至28天的患者与存活者的第一个24小时凝血数据显示,未存活者的抗凝血酶水平较低。此外,使用前72小时内显性DIC和非显性DIC的结果,我们发现抗凝血酶或aPC水平较低均与儿童败血症的显性DIC和非显性DIC相关。需要在更大的儿童败血症病例系列中进行进一步的验证工作。
{"title":"Antithrombin and Activated Protein C in Pediatric Sepsis: Prospective Observational Study of Outcome.","authors":"Tran Dang Xoay, Ta Anh Tuan, Nguyen Thi Ha, Thieu Quang Quan, Nguyen Thi Duyen, Tran Thi Kieu My","doi":"10.1097/PCC.0000000000003677","DOIUrl":"10.1097/PCC.0000000000003677","url":null,"abstract":"<p><strong>Objectives: </strong>To assess antithrombin and activated protein C (aPC) levels in relation to disseminated intravascular coagulation (DIC) and severe outcomes in pediatric sepsis.</p><p><strong>Design: </strong>Prospective, observational study conducted between April 2023 and October 2024. Coagulation profiles including conventional coagulation, antithrombin activity, and aPC were obtained at PICU admission.</p><p><strong>Setting: </strong>PICU in the Vietnam National Children's Hospital, Hanoi, Vietnam.</p><p><strong>Subjects: </strong>PICU admissions, 1 month to 18 years old, with sepsis.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>One hundred thirty children (78 males; median age 7.5 mo) with mortality 23/130 (17.7%). The prevalence of overt DIC was 37 of 130 (28.5%). Nonsurvival at 28 days, compared with survival, was associated with hemorrhage and/or thrombosis at presentation, and higher number of dysfunctional organs, and overt DIC. Those with overt DIC, compared with not, had longer activated partial thromboplastin time, higher international normalized ratio and d -dimer, and lower antithrombin, and aPC. Activity of antithrombin and aPC correlated inversely with the Vasoactive-Inotropic Score in survivors ( p = 0.002 and 0.009, respectively). Patients with a cutoff value for antithrombin less than 63.5% had a mortality risk with area under the receiver operating characteristic (AUROC) curve 0.64, with sensitivity 0.51 and specificity 0.74, and positive predictive value 0.30. Regarding overt DIC, a cutoff value for antithrombin less than 55.5% had an AUROC 0.78, sensitivity 0.72 and specificity of 0.73, and positive predictive value 0.52.</p><p><strong>Conclusions: </strong>In this observational study of pediatric sepsis patients, first 24-hour coagulation data in those who did not-survive to 28 days, vs. survivors showed an associated prior lower level of antithrombin in nonsurvivors. Furthermore, using the outcome of overt DIC and nonovert DIC in the first 72 hours, we found that lower levels of antithrombin or aPC are each associated with overt DIC and nonovert DIC in pediatric sepsis. Further validation work is needed in larger case series of pediatric sepsis.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e197-e205"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phoenix Rising: External Validation of the Phoenix Sepsis Criteria. 凤凰崛起:凤凰败血症标准的外部验证。
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1097/PCC.0000000000003688
Lee A Polikoff
{"title":"Phoenix Rising: External Validation of the Phoenix Sepsis Criteria.","authors":"Lee A Polikoff","doi":"10.1097/PCC.0000000000003688","DOIUrl":"10.1097/PCC.0000000000003688","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e241-e243"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durable Central Venous Access for Pediatric Cardiac Patients: Secondary Analysis of a Single-Center, Retrospective Cohort Study, 2015-2021.
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1097/PCC.0000000000003655
Eran Shostak, Ovadia Dagan, Yelena Tzeitlin, Ori Goldberg, Gal Raz, Gabriel Amir, Yael Feinstein, Ofer Schiller

Objectives: There are several options for durable venous access for pediatric cardiac patients and the insertion techniques, locations, and complications potentially differ. The study aimed to evaluate our experience of upper extremity peripherally inserted central catheters (PICCs) and durable tunneled femoral central venous catheters (TF-CVCs) in young pediatric cardiac ICU (PCICU) patients.

Design: Retrospective cohort study, 2015-2021.

Setting: PCICU in a tertiary medical care center.

Patients: All patients younger than 1.5 years old who underwent bedside insertion of TF-CVC or upper extremity PICC between December 2015 and December 2021.

Interventions: None.

Measurements and main results: The cohort included 226 durable lines, inserted in patients 2-550 days old, with 111 upper extremity PICCs and 115 TF-CVCs. In the two groups, receipt of PICC vs. TF-CVC placement was associated with older age (125.6 vs. 53.4 d; p = 0.005), and shorter duration of mechanical ventilation (9.0 vs. 25.5 d; p < 0.001). PICC vs. TF-CVC use was associated with a higher rate of central line-associated bloodstream infection (CLABSI) (7.14 vs. 2.38/1000 line days; p = 0.004) and more thrombosis events (5 vs. 0; p = 0.008). When adjusted for CLABSI-free line days, TF-CVCs (relative to upper limb PICCs) was associated with close to one-third of the odds of CLABSI (odds ratio [OR], 0.31 [95% CI, 0.13-0.78]); similarly, when adjusted for line days close to one-third of the odds of any complication, that is, CLABSI, dislodgment, occlusion, or thrombosis (OR, 0.31 [95% CI, 0.14-0.65]).

Conclusions: In our 2015-2021 PCICU experience of using durable TF-CVC inserted at the bedside, vs. upper extremity PICCs, in neonates and infants, we found an associated one-third the odds of CLABSI and overall complications. A prospective study of subcutaneous tunneling in various locations of catheters on CLABSI and overall complication rates is needed.

目的:儿科心脏病患者的持久静脉通路有多种选择,插入技术、位置和并发症可能各不相同。本研究旨在评估我们在年轻儿科心脏重症监护病房(PCICU)患者中使用上肢外周插入中心静脉导管(PICC)和耐久性隧道股中心静脉导管(TF-CVC)的经验:设计:2015-2021年回顾性队列研究:背景:一家三级医疗保健中心的 PCICU:所有在 2015 年 12 月至 2021 年 12 月期间接受床旁插入 TF-CVC 或上肢 PICC 的 1.5 岁以下患者:测量和主要结果队列中包括 226 例在 2-550 天内插入的耐用管路,其中 111 例为上肢 PICC,115 例为 TF-CVC。在两组患者中,接受 PICC 与 TF-CVC 置管术的患者年龄较大(125.6 天 vs. 53.4 天;p = 0.005),机械通气时间较短(9.0 天 vs. 25.5 天;p < 0.001)。使用 PICC 与 TF-CVC 相比,中心管路相关血流感染 (CLABSI) 发生率更高(7.14 vs. 2.38/1000 管路天数;p = 0.004),血栓形成事件更多(5 vs. 0;p = 0.008)。当调整无 CLABSI 管路天数时,TF-CVC(相对于上肢 PICC)与接近三分之一的 CLABSI 发生几率相关(几率比 [OR],0.31 [95% CI,0.13-0.78]);同样,当调整管路天数时,接近三分之一的并发症发生几率,即 CLABSI、脱落、闭塞或血栓形成(OR,0.31 [95% CI,0.14-0.65]):在 2015-2021 年 PCICU 对新生儿和婴儿使用床旁插入耐用 TF-CVC 与上肢 PICC 的经验中,我们发现 CLABSI 和总体并发症的相关几率仅为上肢 PICC 的三分之一。我们需要对不同位置导管的皮下隧道插入对 CLABSI 和总体并发症发生率的影响进行前瞻性研究。
{"title":"Durable Central Venous Access for Pediatric Cardiac Patients: Secondary Analysis of a Single-Center, Retrospective Cohort Study, 2015-2021.","authors":"Eran Shostak, Ovadia Dagan, Yelena Tzeitlin, Ori Goldberg, Gal Raz, Gabriel Amir, Yael Feinstein, Ofer Schiller","doi":"10.1097/PCC.0000000000003655","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003655","url":null,"abstract":"<p><strong>Objectives: </strong>There are several options for durable venous access for pediatric cardiac patients and the insertion techniques, locations, and complications potentially differ. The study aimed to evaluate our experience of upper extremity peripherally inserted central catheters (PICCs) and durable tunneled femoral central venous catheters (TF-CVCs) in young pediatric cardiac ICU (PCICU) patients.</p><p><strong>Design: </strong>Retrospective cohort study, 2015-2021.</p><p><strong>Setting: </strong>PCICU in a tertiary medical care center.</p><p><strong>Patients: </strong>All patients younger than 1.5 years old who underwent bedside insertion of TF-CVC or upper extremity PICC between December 2015 and December 2021.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>The cohort included 226 durable lines, inserted in patients 2-550 days old, with 111 upper extremity PICCs and 115 TF-CVCs. In the two groups, receipt of PICC vs. TF-CVC placement was associated with older age (125.6 vs. 53.4 d; p = 0.005), and shorter duration of mechanical ventilation (9.0 vs. 25.5 d; p < 0.001). PICC vs. TF-CVC use was associated with a higher rate of central line-associated bloodstream infection (CLABSI) (7.14 vs. 2.38/1000 line days; p = 0.004) and more thrombosis events (5 vs. 0; p = 0.008). When adjusted for CLABSI-free line days, TF-CVCs (relative to upper limb PICCs) was associated with close to one-third of the odds of CLABSI (odds ratio [OR], 0.31 [95% CI, 0.13-0.78]); similarly, when adjusted for line days close to one-third of the odds of any complication, that is, CLABSI, dislodgment, occlusion, or thrombosis (OR, 0.31 [95% CI, 0.14-0.65]).</p><p><strong>Conclusions: </strong>In our 2015-2021 PCICU experience of using durable TF-CVC inserted at the bedside, vs. upper extremity PICCs, in neonates and infants, we found an associated one-third the odds of CLABSI and overall complications. A prospective study of subcutaneous tunneling in various locations of catheters on CLABSI and overall complication rates is needed.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e137-e145"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Phoenix Sepsis Score Criteria: Exploratory Analysis of Characteristics and Outcomes in an Emergency Transport PICU Cohort From the United Kingdom, 2014-2016. Phoenix脓毒症评分标准的评价:2014-2016年英国紧急运输PICU队列的特征和结果的探索性分析
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1097/PCC.0000000000003682
Michael J Carter, Joshua Hageman, Yael Feinstein, Jethro Herberg, Myrsini Kaforou, Mark J Peters, Simon Nadel, Naomi Edmonds, Nazima Pathan, Michael Levin, Padmanabhan Ramnarayan

Objectives: To assess characteristics and outcomes of children with suspected or confirmed infection requiring emergency transport and PICU admission and to explore the association between the 2024 Phoenix Sepsis Score (PSS) criteria and mortality.

Design: Retrospective analysis of curated data from a 2014-2016 multicenter cohort study.

Setting: PICU admission following emergency transport in South East England, United Kingdom, from April 2014 to December 2016.

Patients: Children 0-16 years old ( n = 663) of whom 444 (67%) had suspected or confirmed infection.

Interventions: None.

Measurements and main results: The PSS was calculated as a sum of four individual organ subscores (respiratory, cardiovascular, neurological, and coagulation) using the worst values during transport (i.e., from referral until the time of PICU admission). A score cutoff of greater than or equal to 2 points was used to define sepsis; and septic shock was defined as sepsis plus 1 or more cardiovascular subscore points. Sepsis occurred in 260 of 444 children (58.6%) with suspected or confirmed infection, with septic shock occurring in 177 of 260 (68.1%) of those with sepsis. A PSS score greater than or equal to 2 points occurred in 37 of 67 bronchiolitis cases, 19 of 35 meningoencephalitis cases, 30 of 47 pneumonia/empyema cases, 38 of 46 septic/toxic shock cases, nine of 15 severe sepsis cases, and 58 of 118 definite viral infections. Overall, 14 of 444 children died (3.2%). There were 12 deaths in the 260 children with PSS greater than or equal to 2, and two deaths in the 184 children with PSS less than 2 (4.6% vs. 1.1%; absolute difference, 3.5%; 95% CI, 0.1-6.9%; p = 0.04).

Conclusions: In 2014-2016, over half of the critically ill children undergoing emergency transport to PICU with presumed or confirmed infection, and meeting retrospectively applied PSS criteria for sepsis, had a range of clinical diagnoses including bronchiolitis, meningoencephalitis, and pneumonia/empyema. Furthermore, the PSS criteria for categorization of sepsis and septic shock were associated with outcome and may be of value in future risk-stratification in clinical trials.

目的:评估疑似或确诊感染需要紧急转运和PICU入院的儿童的特征和结局,并探讨2024 Phoenix脓毒症评分(PSS)标准与死亡率之间的关系。设计:回顾性分析2014-2016年多中心队列研究的整理数据。背景:2014年4月至2016年12月,英国英格兰东南部紧急转运后入院PICU。患者:0-16岁儿童(n = 663),其中444例(67%)疑似或确诊感染。干预措施:没有。测量和主要结果:PSS计算为四个单独器官评分(呼吸、心血管、神经和凝血)的总和,使用运输期间(即从转诊到PICU入院)的最差值。脓毒症采用大于或等于2分的评分截止;脓毒性休克定义为脓毒症加上1个或更多的心血管亚评分。444例疑似或确诊感染患儿中有260例(58.6%)发生脓毒症,260例脓毒症患儿中有177例(68.1%)发生脓毒症休克。67例细支气管炎患者中有37例PSS评分大于等于2分,35例脑膜脑炎患者中有19例,47例肺炎/脓肿患者中有30例,46例脓毒症/中毒性休克患者中有38例,15例严重脓毒症患者中有9例,118例明确病毒感染患者中有58例。总体而言,444名儿童中有14人死亡(3.2%)。260例大于或等于2的PSS患儿中有12例死亡,184例小于2的PSS患儿中有2例死亡(4.6% vs. 1.1%;绝对差,3.5%;95% ci, 0.1-6.9%;P = 0.04)。结论:2014-2016年,超过半数推定或确诊感染并符合回顾性应用PSS脓毒症标准的危重患儿被紧急送往PICU,其临床诊断包括细支气管炎、脑膜脑炎和肺炎/脓胸。此外,PSS对脓毒症和脓毒性休克的分类标准与结果相关,可能对未来临床试验中的风险分层有价值。
{"title":"Evaluation of Phoenix Sepsis Score Criteria: Exploratory Analysis of Characteristics and Outcomes in an Emergency Transport PICU Cohort From the United Kingdom, 2014-2016.","authors":"Michael J Carter, Joshua Hageman, Yael Feinstein, Jethro Herberg, Myrsini Kaforou, Mark J Peters, Simon Nadel, Naomi Edmonds, Nazima Pathan, Michael Levin, Padmanabhan Ramnarayan","doi":"10.1097/PCC.0000000000003682","DOIUrl":"10.1097/PCC.0000000000003682","url":null,"abstract":"<p><strong>Objectives: </strong>To assess characteristics and outcomes of children with suspected or confirmed infection requiring emergency transport and PICU admission and to explore the association between the 2024 Phoenix Sepsis Score (PSS) criteria and mortality.</p><p><strong>Design: </strong>Retrospective analysis of curated data from a 2014-2016 multicenter cohort study.</p><p><strong>Setting: </strong>PICU admission following emergency transport in South East England, United Kingdom, from April 2014 to December 2016.</p><p><strong>Patients: </strong>Children 0-16 years old ( n = 663) of whom 444 (67%) had suspected or confirmed infection.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>The PSS was calculated as a sum of four individual organ subscores (respiratory, cardiovascular, neurological, and coagulation) using the worst values during transport (i.e., from referral until the time of PICU admission). A score cutoff of greater than or equal to 2 points was used to define sepsis; and septic shock was defined as sepsis plus 1 or more cardiovascular subscore points. Sepsis occurred in 260 of 444 children (58.6%) with suspected or confirmed infection, with septic shock occurring in 177 of 260 (68.1%) of those with sepsis. A PSS score greater than or equal to 2 points occurred in 37 of 67 bronchiolitis cases, 19 of 35 meningoencephalitis cases, 30 of 47 pneumonia/empyema cases, 38 of 46 septic/toxic shock cases, nine of 15 severe sepsis cases, and 58 of 118 definite viral infections. Overall, 14 of 444 children died (3.2%). There were 12 deaths in the 260 children with PSS greater than or equal to 2, and two deaths in the 184 children with PSS less than 2 (4.6% vs. 1.1%; absolute difference, 3.5%; 95% CI, 0.1-6.9%; p = 0.04).</p><p><strong>Conclusions: </strong>In 2014-2016, over half of the critically ill children undergoing emergency transport to PICU with presumed or confirmed infection, and meeting retrospectively applied PSS criteria for sepsis, had a range of clinical diagnoses including bronchiolitis, meningoencephalitis, and pneumonia/empyema. Furthermore, the PSS criteria for categorization of sepsis and septic shock were associated with outcome and may be of value in future risk-stratification in clinical trials.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e186-e196"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2024 Phoenix Sepsis Score Criteria: Part 3, What About Using Stages of Sepsis in the Criteria?
IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1097/PCC.0000000000003662
Mark W Hall, Rakesh Lodha, Niranjan Kissoon, Adrienne G Randolph
{"title":"The 2024 Phoenix Sepsis Score Criteria: Part 3, What About Using Stages of Sepsis in the Criteria?","authors":"Mark W Hall, Rakesh Lodha, Niranjan Kissoon, Adrienne G Randolph","doi":"10.1097/PCC.0000000000003662","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003662","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e256-e261"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pediatric Critical Care Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1